Strategic Focus Regional specialty company with focus on oncology, immunology, neuroscience, gastrointestinal and rare diseases in the Middle East and Africa, presenting multiple therapeutic areas for partner in-licensing and co-marketing opportunities.

Partnership Model Offer flexible commercial, regulatory, and medical affairs collaborations, acting as an extension of partner practices in local markets to accelerate market access and launch readiness across multi-country MENA and Africa.

Able-to-Scale Strong leadership and regional execution capability combined with a growing investor-backed network position NewBridge to support multi-country access strategies and rapid on-the-ground deployment for licensed therapies.

Commercial Footprint Existing distribution and commercialization activity in UAE, GCC, Iraq through prior agreements; potential expansion into additional MENA and African markets via new licensing and distribution deals.

Financial Leverage Revenue bracket and substantial funding enable partner-ready opportunities, allowing co-development, market access planning, and channel investments to optimize launches and access programs.